Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

infliximab

- PMLiVE

WHO releases new target product profiles for urgently needed antibiotics

The antibiotics are needed to combat key drug-resistant bacteria causing severe bloodstream and urinary tract infections, pneumonia and meningitis

- PMLiVE

MHRA marks 100 years of patient safety through biological standards

The UK regulator highlights its century-long role in establishing safety and consistency benchmarks

- PMLiVE

Lilly and WHO Foundation partner to support global dementia action plan

The partnership will provide financial support and strengthen early detection and intervention efforts

- PMLiVE

University of Liverpool identifies new class of antibiotic in fight against AMR

The new antibiotic class targets two of the WHO’s ‘priority pathogens’

- PMLiVE

Invivyd working with FDA towards potential Biologics License Application for COVID-19

The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

- PMLiVE

FDA approves Pfizer and BioNTech’s jab for COVID-19

Globally, five billion doses of the companies’ vaccine have been distributed

- PMLiVE

Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

- PMLiVE

EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive

Kostaive is designed to instruct the body to make more mRNA to boost immune response

- PMLiVE

WHO urges US to ‘reconsider’ withdrawal from global health organisation

President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises

- PMLiVE

WHO launches $1.5bn emergency appeal to tackle ongoing health crises

The appeal is aimed at providing urgent humanitarian assistance to more than 300 million people

- PMLiVE

Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

The combined vaccine approach could simplify immunisation practices and lead to higher uptake

- PMLiVE

Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults

Lagevrio is already available in the US under emergency use authorisation to treat certain cases of COVID-19

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links